Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Frontiers in NutritionOpen Access

Dihydromyricetin preserves β-cell function in type 1 diabetes via PI3K/AKT-mediated metabolic reprogramming

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJia LiLLLijia LiTLTa-Hui Lin

Discussion

Loading...

Member takes

Overview

Dietary dihydromyricetin reduces hyperglycemia and preserves β-cell function in type 1 diabetes, indicating its potential as a nutraceutical.

Key Points

  • Dihydromyricetin significantly reduces hyperglycemia and preserves islet architecture in diabetic mice, demonstrating its protective effects.
  • Fasting glycemia and lipid profiles were positively influenced after administering dihydromyricetin over 12 days, confirming its therapeutic potential.
  • Analysis utilized metabolomics and network pharmacology to identify key metabolic shifts and pathway targets including the PI3K/AKT pathway.
  • Findings suggest the potential of dihydromyricetin as a dietary intervention for managing autoimmune diabetes through metabolic modulation.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68e040eda99c246f578b32cbhttps://doi.org/10.3389/fnut.2025.1682308
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dihydromyricetin mitigates T2DM progression by modulating bile acid metabolism through SHP/PPARγ pathway2026
  2. 2Dihydromyricetin improves high glucose induced dopaminergic neuronal damage by activating AMPK-autophagy signaling pathway2024 · 2 citations
  3. 3Study on the Protective Mechanism of Dihydromyricetin Against Aflatoxin B1-Induced Injury in Madin–Darby Canine Kidney Cells2025
  4. 4Si-Miao-Yong-An decoction preserves cardiac function and regulates GLC/AMPK/NF-κB and GLC/PPARα/PGC-1α pathways in diabetic mice2020 · 37 citations
  5. 5Dihydromyricetin promotes GLP-1 secretion to improve insulin resistance via “gut microbiota-CDCA”2024